SLSBio(Specialty Lab Solution Bio) (246250) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SLSBio(Specialty Lab Solution Bio) (246250) reported revenue of 4.0 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20254.0 billion KRW-4.1 billion KRW-4.9 billion KRW[source]
20248.4 billion KRW288 million KRW336 million KRW[source]
20239.0 billion KRW1.0 billion KRW1.4 billion KRW[source]
202210.8 billion KRW2.4 billion KRW2.8 billion KRW[source]
20218.2 billion KRW426 million KRW58 million KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202511.2 billion KRW3.6 billion KRW7.6 billion KRW[source]
202416.4 billion KRW3.8 billion KRW12.5 billion KRW[source]
202317.8 billion KRW4.4 billion KRW13.5 billion KRW[source]
202211.8 billion KRW5.0 billion KRW6.7 billion KRW[source]
202110.5 billion KRW6.8 billion KRW3.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice